| Dhruval Harilal Patel, MD | |
|
1021 Gilpin Ave Ste 203, Wilmington, DE 19806-3272 | |
| (027) 228-8003 | |
| (302) 722-8784 |
| Full Name | Dhruval Harilal Patel |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 14 Years |
| Location | 1021 Gilpin Ave Ste 203, Wilmington, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912101502 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | C1-0009983 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| American Universal - Hockessin | Hockessin, DE | Dialysis facility |
| Fresenius Medical Care Wilmington | Wilmington, DE | Dialysis facility |
| Christiana Hospital | Newark, DE | Hospital |
| St Francis Hospital | Wilmington, DE | Hospital |
| Bayhealth Hospital, Kent Campus | Dover, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kidney Care Associates Pa | 1052710852 | 3 |
News Archive
A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.
Lay persons in many countries who are given special training to promote or carry out some health care services may reduce childhood mortality.
Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.
A new study from Rigshospitalet and EDMaRC finds a strong association between late onset of puberty and subsequent semen quality. This is the first study of its kind to investigate the influence of pubertal timing on male reproductive health.
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
› Verified 1 days ago
| Entity Name | Delaware Post Acute Medical Services 1 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801325717 PECOS PAC ID: 2466727755 Enrollment ID: O20171012002816 |
News Archive
A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.
Lay persons in many countries who are given special training to promote or carry out some health care services may reduce childhood mortality.
Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.
A new study from Rigshospitalet and EDMaRC finds a strong association between late onset of puberty and subsequent semen quality. This is the first study of its kind to investigate the influence of pubertal timing on male reproductive health.
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
› Verified 1 days ago
| Entity Name | De Pacs 2 Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457837981 PECOS PAC ID: 0244580926 Enrollment ID: O20180829003337 |
News Archive
A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.
Lay persons in many countries who are given special training to promote or carry out some health care services may reduce childhood mortality.
Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.
A new study from Rigshospitalet and EDMaRC finds a strong association between late onset of puberty and subsequent semen quality. This is the first study of its kind to investigate the influence of pubertal timing on male reproductive health.
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
› Verified 1 days ago
| Entity Name | Kidney Care Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861071060 PECOS PAC ID: 1052710852 Enrollment ID: O20210527002353 |
News Archive
A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.
Lay persons in many countries who are given special training to promote or carry out some health care services may reduce childhood mortality.
Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.
A new study from Rigshospitalet and EDMaRC finds a strong association between late onset of puberty and subsequent semen quality. This is the first study of its kind to investigate the influence of pubertal timing on male reproductive health.
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dhruval Harilal Patel, MD 1021 Gilpin Ave Ste 203, Wilmington, DE 19806-3272 Ph: (302) 722-8800 | Dhruval Harilal Patel, MD 1021 Gilpin Ave Ste 203, Wilmington, DE 19806-3272 Ph: (027) 228-8003 |
News Archive
A new study describes the promising results of a new drug candidate in combating the illness caused by the binding of COVID-19-specific antibodies to infected cells.
Lay persons in many countries who are given special training to promote or carry out some health care services may reduce childhood mortality.
Savient Pharmaceuticals, Inc. today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.
A new study from Rigshospitalet and EDMaRC finds a strong association between late onset of puberty and subsequent semen quality. This is the first study of its kind to investigate the influence of pubertal timing on male reproductive health.
The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.
› Verified 1 days ago
Dr. Shady Abdelbaki, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 501 W 14th St, Wilmington, DE 19801 Phone: 302-320-2490 Fax: 302-623-4395 | |
Terry L Horton, MD Nephrology Medicare: Medicare Enrolled Practice Location: 501 W 14th St, Room 5236, Wilmington, DE 19801 Phone: 302-428-4574 Fax: 302-428-2569 | |
Dr. Susan M Keith, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1601 Kirkwood Hwy, Wilmington, DE 19805 Phone: 302-633-5302 Fax: 302-633-5582 | |
Dr. Melissa D. Morgan-gouveia, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 501 W 14th St, Wilmington Hospital - Adult Medicine Office, Wilmington, DE 19801 Phone: 302-428-4411 Fax: 302-428-4667 | |
Dr. Alfonso Paul Ciarlo, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5311 Limestone Road, Suite 100, Wilmington, DE 19808 Phone: 302-234-2200 Fax: 302-234-2262 | |
Dr. Robert Anselmo Jakubowski, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 501 W 14th St Fl 6, Wilmington, DE 19801 Phone: 302-320-1300 Fax: 302-320-1373 | |
Dr. Brajesh Narayan Agarwal, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1601 Kirkwood Hwy, Medical Service (111), Wilmington, DE 19805 Phone: 302-633-5302 Fax: 302-633-5582 |